Cabaletta Bio, Inc. EBITDA
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| EBITDA | $83.3K | ($6,009.0K) | ($18.7M) | ($33.5M) | ($45.6M) | ($53.0M) | ($73.2M) |
Cabaletta Bio, Inc. (CABA) EBITDA comparison analysis
General
LTM EBITDA
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
CABA key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.4 | 0.7 | 3.7 | 1.4 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.1) 0.0% | (0.4) 0.0% | (0.7) 0.0% | (3.7) 0.0% | (1.4) 0.0% |
| Operating Expenses | 0.3 | 6.2 | 18.7 | 33.8 | 46.3 | 54.1 | 74.7 |
| Research & Development Expenses (R&D) | 0.0 | 4.5 | 11.7 | 21.4 | 32.5 | 39.3 | 55.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.3 | 1.7 | 7.0 | 12.5 | 13.8 | 14.8 | 19.2 |
% margin | (0.3) 0.0% | (6.2) 0.0% | (18.7) 0.0% | (33.8) 0.0% | (46.3) 0.0% | (54.1) 0.0% | (74.7) 0.0% |
| Interest Income | 0.0 | 0.2 | 1.7 | 0.5 | 0.0 | 1.2 | 7.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (0.3) | (12.2) | (16.9) | (33.3) | (46.3) | (53.0) | (67.7) |
% effective tax rate | (0.3) 133.3% | (0.2) 1.9% | (1.8) 10.9% | (0.8) 2.5% | (0.8) 1.6% | (1.2) 2.2% | 0.0 0.0% |
% margin | (0.3) 0.0% | (12.2) 0.0% | (15.1) 0.0% | (32.5) 0.0% | (45.5) 0.0% | (51.8) 0.0% | (67.7) 0.0% |
| EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
| Diluted EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
% margin | 0.1 0.0% | (6.0) 0.0% | (18.7) 0.0% | (33.5) 0.0% | (45.6) 0.0% | (53.0) 0.0% | (73.2) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Cabaletta Bio, Inc.'s EBITDA?
As of today, Cabaletta Bio, Inc.'s last 12-month EBITDA is ($112.9M), based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Cabaletta Bio, Inc.'s EBITDA growth rate?
Over the last year, Cabaletta Bio, Inc.'s EBITDA growth was 70.1%. The average annual EBITDA growth rates for Cabaletta Bio, Inc. have been 47.4% over the past three years, 66.7% over the past five years.
3) Is Cabaletta Bio, Inc.'s EBITDA growth rate Good?
Over the last year, Cabaletta Bio, Inc.'s EBITDA growth was 70.1%, which is higher than industry growth of (0.1%). It indicates that Cabaletta Bio, Inc.'s EBITDA growth is Good.